Anti-BCMA/CD19 CAR T Cell Therapy in Patients with Refractory Generalized Myasthenia Gravis: A Single-Arm, Phase I Trial

Researchers developed autologous anti-B-cell maturation antigen (BCMA) and CD19 bispecific CAR T cells to evaluate the safety and efficacy in refractory myasthenia gravis.